UA83022C2 - Аплідин для комбінованої терапії лейкозу та лімфоми - Google Patents

Аплідин для комбінованої терапії лейкозу та лімфоми

Info

Publication number
UA83022C2
UA83022C2 UAA200508279A UAA200508279A UA83022C2 UA 83022 C2 UA83022 C2 UA 83022C2 UA A200508279 A UAA200508279 A UA A200508279A UA A200508279 A UAA200508279 A UA A200508279A UA 83022 C2 UA83022 C2 UA 83022C2
Authority
UA
Ukraine
Prior art keywords
aplidine
lymphoma
leukemia
combination therapies
treatment
Prior art date
Application number
UAA200508279A
Other languages
English (en)
Russian (ru)
Inventor
Дебабрата Барнеджі
Джозеф Р. Бертіно
Глінн Томас Ферклот
Сайдам Гурей
Хосе Хімено
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of UA83022C2 publication Critical patent/UA83022C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід стосується застосування аплідину або аналога аплідину для одержання лікарського засобу для лікування лейкемії або лімфоми за допомогою комбінованої терапії з іншим лікарським засобом, вибраним з метотрексату, цитозину арабінозиду, мітоксантрону, вінбластину, метилпреднізолону і доксорубіцину.
UAA200508279A 2003-03-12 2004-03-12 Аплідин для комбінованої терапії лейкозу та лімфоми UA83022C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
PCT/US2004/007606 WO2004080421A2 (en) 2003-03-12 2004-03-12 Improved antitumoral treatments

Publications (1)

Publication Number Publication Date
UA83022C2 true UA83022C2 (uk) 2008-06-10

Family

ID=32990868

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200508279A UA83022C2 (uk) 2003-03-12 2004-03-12 Аплідин для комбінованої терапії лейкозу та лімфоми
UAA200509530A UA82089C2 (uk) 2003-03-12 2004-12-03 Аплідин для лікування множинної мієломи

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200509530A UA82089C2 (uk) 2003-03-12 2004-12-03 Аплідин для лікування множинної мієломи

Country Status (13)

Country Link
US (2) US7576188B2 (uk)
EP (1) EP1620117A4 (uk)
JP (1) JP2006519848A (uk)
KR (1) KR20060002778A (uk)
CN (3) CN101579520A (uk)
AU (1) AU2004220451B2 (uk)
CA (1) CA2516572A1 (uk)
MX (1) MXPA05009741A (uk)
NO (1) NO20053947L (uk)
NZ (1) NZ541634A (uk)
RU (1) RU2341283C2 (uk)
UA (2) UA83022C2 (uk)
WO (1) WO2004080421A2 (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
KR100518986B1 (ko) * 1999-11-15 2005-10-06 파르마 마르, 에스.에이. 아플리딘을 사용하여 암을 치료하는 방법
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
HK1054191A1 (zh) 2000-10-12 2003-11-21 Pharma Mar, S.A. 施用aplidine時同時使用myoprotector的癌症治療
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
ATE406171T1 (de) 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
US8258098B2 (en) * 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
WO2008135793A1 (en) * 2007-05-04 2008-11-13 Pharma Mar S.A. Combination of aplidine and carboplatin in anticancer treatments
JP2011500650A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
AU2009221720A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
WO2010029158A1 (en) * 2008-09-12 2010-03-18 Pharma Mar, S.A. Aplidine in the treatment of chronic myeloproliferative disorders
CN104706599B (zh) * 2013-12-11 2020-10-02 中国海洋大学 一种携带膜海鞘素化合物的冻干粉针剂
US11013698B2 (en) 2016-03-15 2021-05-25 Oryzon Genomics S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
ATE74761T1 (de) * 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) * 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5018188A (en) 1989-12-20 1991-05-21 Motorola, Inc. Microphone-controller with multifunction, single conductor
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5482726A (en) * 1992-07-14 1996-01-09 Us Harvest Technologies Corporation Method for reducing contamination of shellfish
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
ATE208323T1 (de) 1996-07-03 2001-11-15 Paxton C G Ltd Behälter
JP2001503746A (ja) 1996-10-24 2001-03-21 ザ・ボード・オブ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・イリノイ ジデムニン類似体の半合成法
ES2202644T3 (es) 1996-10-24 2004-04-01 The Board Of Trustees Of The University Of Illinois Sintesis total del analogo hip amino de la didemnin a.
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
EP0981352B8 (en) * 1997-05-07 2009-06-17 Pharma Mar, S.A. Use of aplidine for the treatment of cardiovascular diseases
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
GB9821975D0 (en) * 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
KR100518986B1 (ko) * 1999-11-15 2005-10-06 파르마 마르, 에스.에이. 아플리딘을 사용하여 암을 치료하는 방법
SE9904175D0 (sv) 1999-11-18 1999-11-18 Pharmacia & Upjohn Diag Ab Assay device and use thereof
IL152111A0 (en) 2000-04-07 2003-07-31 Univ Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
AU6836301A (en) * 2000-06-20 2002-01-02 Idec Pharma Corp Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU2001294024C1 (en) * 2000-10-12 2006-11-23 Pharma Mar, S.A. Treatment of cancers by aplidine in conjunction with a myoprotector
HK1054191A1 (zh) * 2000-10-12 2003-11-21 Pharma Mar, S.A. 施用aplidine時同時使用myoprotector的癌症治療
JP2004521112A (ja) * 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
ATA13422001A (de) 2001-08-23 2003-09-15 Plasser Bahnbaumasch Franz Maschine zur bearbeitung einer gleisbettung
ES2315404T3 (es) 2001-10-19 2009-04-01 Pharma Mar, S.A. Uso de aplidina para el tratamiento de cancer de pancreas.
ATE406171T1 (de) 2003-03-12 2008-09-15 Dana Farber Cancer Inst Inc Aplidine zur behandlung von multiplem myelom
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
CN101579520A (zh) 2009-11-18
WO2004080421A3 (en) 2005-06-09
CN1753684A (zh) 2006-03-29
KR20060002778A (ko) 2006-01-09
EP1620117A4 (en) 2009-07-29
CN100409895C (zh) 2008-08-13
AU2004220451B2 (en) 2010-01-21
WO2004080421A2 (en) 2004-09-23
US7576188B2 (en) 2009-08-18
MXPA05009741A (es) 2005-11-16
RU2005126819A (ru) 2006-01-20
US20090227490A1 (en) 2009-09-10
NO20053947D0 (no) 2005-08-24
RU2341283C2 (ru) 2008-12-20
NZ541634A (en) 2008-08-29
CN1761480B (zh) 2012-09-26
NO20053947L (no) 2005-12-07
CN1761480A (zh) 2006-04-19
CA2516572A1 (en) 2004-09-23
EP1620117A2 (en) 2006-02-01
JP2006519848A (ja) 2006-08-31
US20060178298A1 (en) 2006-08-10
AU2004220451A1 (en) 2004-09-23
UA82089C2 (uk) 2008-03-11

Similar Documents

Publication Publication Date Title
MX2023009135A (es) Compuestos de oxazepina tetraciclica y usos de estos.
WO2004034990A3 (en) Methods and compositions for use in treating cancer
CA105223S (en) Sponge
GB2435590A (en) An interleaver and associated methods
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
NO983429D0 (no) Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
WO2004080421A3 (en) Improved antitumoral treatments
WO2007101235A3 (en) Improved antitumoral treatments
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
TW200600091A (en) Sulfonylethyl phosphorodiamidates
AU2158601A (en) Antiviral agent for use in treatment of cancer
MX2007009908A (es) Metodos para tratar linfomas utilizando una combinacion de un agente quimioterapeutico e il-2 y opcionalmente un anticuerpo anti-cd20.
AU301493S (en) Reciprocating saw
TW200510398A (en) Novel compounds
TW200641091A (en) Organometallic complexes
AU302267S (en) Console
TW200509935A (en) Novel compounds
PT1603584E (pt) Aplidina para o tratamento de mieloma múltiplo
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
AU301497S (en) Reciprocating saw
AU305719S (en) Operator for writing instrument
TR200302193T4 (tr) Kombinasyon kemoterapisi.
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
MX2007006206A (es) Combinacion de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3, 4-oxadia zol-2-il]-fenil)-piridin-3-sulfonamida y un agente antimitotico para el tratamiento del cancer.